Correlation Between FlowMet™ and Other Gold Standard Assessments in the Management of Critical Limb Ischemia (CLI)
NCT ID: NCT03094559
Last Updated: 2017-04-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2017-03-07
2018-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Use of FlowMet-R Technology to Predict Wound Healing in CLI Patients in a Wound Care Center Setting
NCT05455554
FlowMet-R Blood Flow Measurement for the Diagnosis of Peripheral Artery Disease and Critical Limb Ischemia
NCT04120610
Peripheral Microvascular Resistance as a Predictor for Limb Salvage
NCT06014242
Imaging-Guided Vessel Sizing in the Tibial Arteries
NCT04748965
Evaluate the Correlation of NIRS, ABI, Exercise, baPWV and Albuminuria With Peripheral Artery Occlusion Disease (PAD) and Other Atherosclerosis Outcomes
NCT03378024
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1.0
To demonstrate that the FlowMet is effective for the assessment of tissue perfusion compared to gold standard technologies in patients suspected of or being treated for CLI.
2.0 STUDY DESIGN
This is a single center, cross-sectional study of subjects who are scheduled for CLI assessment with a Rutherford score of V and VI.
The subjects will be evaluated at baseline for determination if they meet the inclusion/exclusion criteria of the protocol. If the subject is eligible to enroll in the trial and they have signed an informed consent form (ICF) and are scheduled for evaluation, they will be enrolled. Subjects will undergo FlowMet, ABI, SPP, TBI, TcPO2, and angiography measurements (if not performed previously). The correlation between the aforementioned standard clinical measurements and FlowMet measurements will be assessed.
As ABI, SPP, TBI, TcPO2, Rutherford score, time of surgical (re)admission, speed of wound healing, and angiography measurements will likely change over a period of one year following initial FlowMet measurements, future measurements up to one year post FlowMet measurement (and performed as a standard of care) may also be correlated to initial FlowMet measurements to assess the whether FlowMet data is correlated to long-term patient outcomes.
3.0 STUDY PROCEDURES
3.1 Randomization, Blinding and Subject Identification
This is a cross-sectional study of subjects being treated for CLI with a Rutherford score of V or VI. No randomization scheme is required.
3.2 Product Equipment (FlowMet)
All parts of the FlowMet were manufactured in facilities with ISO 9001:2008 certification. Instruments are constructed in an ISO 9 cleanroom. All materials intended to be in contact with the patient's skin are constructed of polydimethylsiloxane (silicone) rubber which was sterilized via autoclave prior to device construction. Polydimethylsiloxane is widely used in existing medical devices and has been shown to be safe for both short-term contact, as well as long-term implantation (The AMS Sphincter 800™ Urinary Prosthesis, PMA P000053). Between uses, all polydimethylsiloxane components, in addition to all components which can accidentally contact a patient's skin during use, can be sanitized using alcohol wipes or germicidal wipes, such as alcohoPSI Inc. Sani-Cloths, which are commonly used in hospitals and which are bactericidal, tuberculocidal, and virucidal. The FlowMet has been used on 37 patients without adverse events at the University of California, Irvine in a study of tissue optical properties approved and overseen by the University of California, Irvine IRB. The FlowMet has not been evaluated, cleared or approved for use by the FDA.
3.3 Details of FlowMet usage
Extremity perfusion measurements will be performed using the FlowMet peripheral perfusion device. All extremity blood flow measurements will be collected during room air inhalation.
3.3.1
i. The FlowMet device will be placed on the index finger of the right hand. Signal fidelity will be assured by confirming the presence of a pulse waveform if one is expected and by assuring that an appropriate amount of light is be detected by the FlowMet device. The following light intensity values are acceptable: maximum intensity greater than 25 but less than 255 and average subtracted intensity greater than 20 but less than 175.
ii. Following placement of the FlowMet device, a period of 10 seconds will be allowed to elapse to allow transient changes in perfusion due to device placement to diminish.
iii. FlowMet blood flow data will be recorded for 20 seconds using the FlowMet data acquisition software.
iv. Steps i-iii will be repeated for digits 1 and 2 on the limb with diagnosed or suspected CLI, or on both limbs if both are diagnosed or suspected of having CLI. All data sets will be saved, and blood flow in each digit will be computed as the average of the collected data over the 20 second data collection period. If alternative digits are used for data acquisition due to differences in physiology, this will be recorded. If subject is missing the aforementioned toes, the tester will choose a different set of digits and this change will be recorded.
4.0 STUDY PROCEDURES
4.1 Baseline and Assessment
The Cleveland Clinic's standard of care will be followed for all participating study subjects. The following procedures will be conducted as part of a baseline assessment:
* Informed consent
* Complete medical history
* Demographics
* Vital signs (heart rate and blood pressure), height and weight
* Record angiographic data for study (if available)
The following procedures are standard of care and will be conducted to assess perfusion:
* Ankle brachial pulse index (ABI)
* Skin Perfusion Pressure (SPP)
* Toe brachial pulse index (TBI)
* Transcutaneous oxygen tension (TcP02)
* Angiography (if not performed previously)
The following procedures are not standard of care and will be conducted to assess perfusion:
* FlowMet measurement on subject's hand and foot/feet
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
FlowMet device
This is a feasibility study
FlowMet
The FlowMet device will be placed on the index finger of the right hand. Signal fidelity will be assured by confirming the presence of a pulse waveform if one is expected and by assuring that an appropriate amount of light is be detected by the FlowMet device. Following placement of the FlowMet device, a period of 10 seconds will be allowed to elapse to allow transient changes in perfusion due to device placement to diminish. FlowMet blood flow data will be recorded for 20 seconds using the FlowMet data acquisition software. These steps will be repeated for digits 1 and 2 on the limb with diagnosed or suspected CLI, or on both limbs if both are diagnosed or suspected of having CLI.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FlowMet
The FlowMet device will be placed on the index finger of the right hand. Signal fidelity will be assured by confirming the presence of a pulse waveform if one is expected and by assuring that an appropriate amount of light is be detected by the FlowMet device. Following placement of the FlowMet device, a period of 10 seconds will be allowed to elapse to allow transient changes in perfusion due to device placement to diminish. FlowMet blood flow data will be recorded for 20 seconds using the FlowMet data acquisition software. These steps will be repeated for digits 1 and 2 on the limb with diagnosed or suspected CLI, or on both limbs if both are diagnosed or suspected of having CLI.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject is willing and able to comply with the study procedures.
* Subject is able to understand the study procedures.
* Subject is being seen at the clinic for the evaluation/treatment of CLI.
* Subject has a Rutherford score of V or VI.
Exclusion Criteria
* Anyone with a latex allergy
* Must be over 18 years old
* Must not be pregnant during time of study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Cleveland Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mehdi Shishehbor
Role: PRINCIPAL_INVESTIGATOR
The Cleveland Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cleveland Clinic
Cleveland, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Anderson RR, Parrish JA. The optics of human skin. J Invest Dermatol. 1981 Jul;77(1):13-9. doi: 10.1111/1523-1747.ep12479191.
Wilson BC, Adam G. A Monte Carlo model for the absorption and flux distributions of light in tissue. Med Phys. 1983 Nov-Dec;10(6):824-30. doi: 10.1118/1.595361.
Got I. [Transcutaneous oxygen pressure (TcPO2): advantages and limitations]. Diabetes Metab. 1998 Sep;24(4):379-84. French.
Zwicky S, Mahler F, Baumgartner I. Evaluation of clinical tests to assess perfusion in chronic critical limb ischemia. Vasa. 2002 Aug;31(3):173-8. doi: 10.1024/0301-1526.31.3.173.
Jakobsson A, Nilsson GE. Prediction of sampling depth and photon pathlength in laser Doppler flowmetry. Med Biol Eng Comput. 1993 May;31(3):301-7. doi: 10.1007/BF02458050.
Sprengers RW, Teraa M, Moll FL, de Wit GA, van der Graaf Y, Verhaar MC; JUVENTAS Study Group; SMART Study Group. Quality of life in patients with no-option critical limb ischemia underlines the need for new effective treatment. J Vasc Surg. 2010 Oct;52(4):843-9, 849.e1. doi: 10.1016/j.jvs.2010.04.057.
Varu VN, Hogg ME, Kibbe MR. Critical limb ischemia. J Vasc Surg. 2010 Jan;51(1):230-41. doi: 10.1016/j.jvs.2009.08.073.
Hirsch AT, Hartman L, Town RJ, Virnig BA. National health care costs of peripheral arterial disease in the Medicare population. Vasc Med. 2008 Aug;13(3):209-15. doi: 10.1177/1358863X08089277.
Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II Working Group; Bell K, Caporusso J, Durand-Zaleski I, Komori K, Lammer J, Liapis C, Novo S, Razavi M, Robbs J, Schaper N, Shigematsu H, Sapoval M, White C, White J, Clement D, Creager M, Jaff M, Mohler E 3rd, Rutherford RB, Sheehan P, Sillesen H, Rosenfield K. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33 Suppl 1:S1-75. doi: 10.1016/j.ejvs.2006.09.024. Epub 2006 Nov 29. No abstract available.
Falanga V. Wound healing and its impairment in the diabetic foot. Lancet. 2005 Nov 12;366(9498):1736-43. doi: 10.1016/S0140-6736(05)67700-8.
Ouriel K. Peripheral arterial disease. Lancet. 2001 Oct 13;358(9289):1257-64. doi: 10.1016/S0140-6736(01)06351-6.
Cronberg CN, Sjoberg S, Albrechtsson U, Leander P, Lindh M, Norgren L, Danielsson P, Sonesson B, Larsson EM. Peripheral arterial disease. Contrast-enhanced 3D MR angiography of the lower leg and foot compared with conventional angiography. Acta Radiol. 2003 Jan;44(1):59-66.
Stadelmann WK, Digenis AG, Tobin GR. Impediments to wound healing. Am J Surg. 1998 Aug;176(2A Suppl):39S-47S. doi: 10.1016/s0002-9610(98)00184-6.
Mosely LH, Finseth F. Cigarette smoking: impairment of digital blood flow and wound healing in the hand. Hand. 1977 Jun;9(2):97-101. doi: 10.1016/s0072-968x(77)80001-6.
Prahl, S. A., Keijzer, M., Jacques, S. L. & Welch, A. J., SPIE Proceedings of Dosimetry of Laser Radiation in Medicine and Biology. 102-111 (Proc. SPIE IS 5, 1989).
Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American Association for Vascular Surgery; Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines; American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; Vascular Disease Foundation. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol. 2006 Mar 21;47(6):1239-312. doi: 10.1016/j.jacc.2005.10.009. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16-1223
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.